Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma

Philip Friedlander; William Simpson; Cora Cajulis

doi:10.1007/978-3-030-29236-2_6

Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

The prognosis of patients with stage IV melanoma is improving through the use of molecularly targeted therapy that inhibits the activity of the BRAF protein and the use of immunotherapies that block regulatory checkpoints. Interval performance of imaging studies is needed to determine treatment efficacy. Traditionally, enlargement of a metastasis or the development of new lesions would signify tumor progression and insufficient treatment efficacy. Immunotherapy can cause immune cells to infiltrate tumors leading to initial enlargement of metastases on imaging termed pseudo-progression. This chapter reviews advances in systemic treatment of metastatic melanoma and novel strategies to monitor for efficacy in the context of immunotherapy and molecularly targeted therapy.

Original language	English
Title of host publication	Image Guided Dermatologic Treatments
Publisher	Springer International Publishing
Pages	57-71
Number of pages	15
ISBN (Electronic)	9783030292362
ISBN (Print)	9783030292348
DOIs	https://doi.org/10.1007/978-3-030-29236-2_6
State	Published - 1 Jan 2019

Access to Document

10.1007/978-3-030-29236-2_6

Cite this

@inbook{6b5250abb37143199220bd8a74da2695,

title = "Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma",

abstract = "The prognosis of patients with stage IV melanoma is improving through the use of molecularly targeted therapy that inhibits the activity of the BRAF protein and the use of immunotherapies that block regulatory checkpoints. Interval performance of imaging studies is needed to determine treatment efficacy. Traditionally, enlargement of a metastasis or the development of new lesions would signify tumor progression and insufficient treatment efficacy. Immunotherapy can cause immune cells to infiltrate tumors leading to initial enlargement of metastases on imaging termed pseudo-progression. This chapter reviews advances in systemic treatment of metastatic melanoma and novel strategies to monitor for efficacy in the context of immunotherapy and molecularly targeted therapy.",

author = "Philip Friedlander and William Simpson and Cora Cajulis",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2020.",

year = "2019",

month = jan,

day = "1",

doi = "10.1007/978-3-030-29236-2\_6",

language = "English",

isbn = "9783030292348",

pages = "57--71",

booktitle = "Image Guided Dermatologic Treatments",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma

AU - Friedlander, Philip

AU - Simpson, William

AU - Cajulis, Cora

N1 - Publisher Copyright: © Springer Nature Switzerland AG 2020.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The prognosis of patients with stage IV melanoma is improving through the use of molecularly targeted therapy that inhibits the activity of the BRAF protein and the use of immunotherapies that block regulatory checkpoints. Interval performance of imaging studies is needed to determine treatment efficacy. Traditionally, enlargement of a metastasis or the development of new lesions would signify tumor progression and insufficient treatment efficacy. Immunotherapy can cause immune cells to infiltrate tumors leading to initial enlargement of metastases on imaging termed pseudo-progression. This chapter reviews advances in systemic treatment of metastatic melanoma and novel strategies to monitor for efficacy in the context of immunotherapy and molecularly targeted therapy.

AB - The prognosis of patients with stage IV melanoma is improving through the use of molecularly targeted therapy that inhibits the activity of the BRAF protein and the use of immunotherapies that block regulatory checkpoints. Interval performance of imaging studies is needed to determine treatment efficacy. Traditionally, enlargement of a metastasis or the development of new lesions would signify tumor progression and insufficient treatment efficacy. Immunotherapy can cause immune cells to infiltrate tumors leading to initial enlargement of metastases on imaging termed pseudo-progression. This chapter reviews advances in systemic treatment of metastatic melanoma and novel strategies to monitor for efficacy in the context of immunotherapy and molecularly targeted therapy.

UR - https://www.scopus.com/pages/publications/105006862235

U2 - 10.1007/978-3-030-29236-2_6

DO - 10.1007/978-3-030-29236-2_6

M3 - Chapter

AN - SCOPUS:105006862235

SN - 9783030292348

SP - 57

EP - 71

BT - Image Guided Dermatologic Treatments

PB - Springer International Publishing

ER -

Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma

Abstract

Access to Document

Fingerprint

Cite this